Compounds > lopinavir
Page last updated: 2024-08-26

lopinavir and Lipodystrophy

lopinavir has been researched along with Lipodystrophy in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (44.44)29.6817
2010's5 (55.56)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Belloso, WH; Boyd, MA; Cooper, DA; Emery, S; Ferret, S; Hoy, JF; Mallon, PW; Martin, A; Moore, CL; Phanuphak, P1
Amogne, W; Assefa, G; Caulk, AW; Getenet, H; Gleason, RL; Parker, I; Seifu, D; Vidakovic, B1
Cai, W; Caughey, B; Chung, C; Dai, Z; Hu, F; Lan, Y; Li, L; Tang, X; Zhang, K1
Brinkman, K; Danner, SA; Geerlings, SE; Hassink, EA; Milinkovic, A; Reiss, P; Ristola, M; van Agtmael, MA; van Eeden, A; van Vonderen, MG1
Bruce-Keller, AJ; Gupta, S; Ingram, DK; Keller, JN; Knight, AG; Losso, BY1
Arribas, JR; Arrizabalaga, J; Bernardino, JI; Domingo, P; Martinez, E; Muñoz, J; Ocampo, A; Portilla, J; Pulido, F; Torres, R1
Phillips, E; Rachlis, A; Sullivan, JR1
Currie, A; Fiedorek, FT; Grasela, DM; Haas, DW; Hodder, SL; Noor, MA; O'Mara, E; Parker, RA1
Andres, DA; Coffinier, C; Farber, EA; Fong, LG; Hrycyna, CA; Hudon, SE; Lee, R; Miner, JH; Nobumori, C; Spielmann, HP; Young, SG1

Trials

4 trial(s) available for lopinavir and Lipodystrophy

ArticleYear
HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Adult; Anti-HIV Agents; Body Fat Distribution; Body Mass Index; Cardiovascular Diseases; Cholesterol; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipodystrophy; Logistic Models; Lopinavir; Male; Metabolic Syndrome; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; RNA, Viral; Viral Load; Virus Replication

2013
Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.
    PloS one, 2009, May-21, Volume: 4, Issue:5

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Biomarkers; Body Composition; Glucose; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lipodystrophy; Lopinavir; Male; Middle Aged; Pyrimidinones; Zidovudine

2009
Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:6

    Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Antiretroviral Therapy, Highly Active; Atrophy; Body Composition; Chemistry, Pharmaceutical; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Intention to Treat Analysis; Lamivudine; Lipids; Lipodystrophy; Lopinavir; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure

2013
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
    AIDS (London, England), 2004, Nov-05, Volume: 18, Issue:16

    Topics: Adult; Analysis of Variance; Atazanavir Sulfate; Cross-Over Studies; Double-Blind Method; Energy Metabolism; Fatty Acids, Nonesterified; Glycogen; HIV Protease Inhibitors; HIV Seronegativity; Humans; Insulin Resistance; Lipids; Lipodystrophy; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones

2004

Other Studies

5 other study(ies) available for lopinavir and Lipodystrophy

ArticleYear
Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Atherosclerosis; Benzoxazines; Biomarkers; Blood Pressure; C-Reactive Protein; Carotid Intima-Media Thickness; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Ethiopia; Female; Heart Rate; HIV Infections; HIV-1; Humans; Lipodystrophy; Lopinavir; Male; Middle Aged; Nevirapine; Pulse Wave Analysis; Ritonavir; Triglycerides

2015
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
    Current molecular medicine, 2015, Volume: 15, Issue:10

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Case-Control Studies; Cyclopropanes; DNA, Mitochondrial; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Lopinavir; Male; Middle Aged; Mitochondria; Nelfinavir; Predictive Value of Tests; Ritonavir; ROC Curve; Stavudine; Zidovudine

2015
Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.
    Antiviral research, 2012, Volume: 95, Issue:1

    Topics: Animals; Brain Injuries; Cerebral Cortex; Hippocampus; HIV Protease Inhibitors; Hyperlipidemias; Insulin Resistance; Lipodystrophy; Lopinavir; Male; Mice; Mice, Inbred C57BL; Ritonavir

2012
'Buffalo-hump' dermatitis: a hat trick of antiretroviral side-effects.
    Contact dermatitis, 2003, Volume: 48, Issue:3

    Topics: Anti-HIV Agents; Dermatitis, Irritant; Diagnosis, Differential; Drug Eruptions; HIV Infections; Humans; Lipodystrophy; Lopinavir; Male; Middle Aged; Nevirapine; Pyrimidinones

2003
A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.
    The Journal of biological chemistry, 2008, Apr-11, Volume: 283, Issue:15

    Topics: Animals; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Lamin Type A; Lipodystrophy; Lopinavir; Membrane Proteins; Metabolic Syndrome; Metalloendopeptidases; Mice; Mice, Knockout; Nuclear Proteins; Protein Precursors; Protein Processing, Post-Translational; Pyrimidinones; Ritonavir; Sulfonamides

2008